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INTRODUCTION 
Parkinson’s disease is a neurological syndrome secondary to diminished levels of 
dopamine in the corpus striatum of the cerebrum.’ This disease is manifested by the 
classic clinical constellation of bradykinesia, rigidity, tremor and postural changes. 
The treatment of Parkinson’s disease was significantly advanced with the introduction 
of levodopa, a metabolic precursor of dopamine. However, after five years of levodopa 
therapy, 50% of patients develop fluctuating motor responses, the “on-off” phenome- 
non, to drug treatment which can be disabling and in many cases poorly controlled by 
conservative therapy.2 These fluctuations range from excessive involuntary dyskinetic 
movements to akinesia. Since plasma levels of levodopa are high during periods of 
mobility with dyskinesias and low during episodes of immobility, a constant drug 
infusion may provide stable plasma drug levels and control this clinical problem.’ 
Several investigators have used a constant intravenous infusion of levodopa to 
control the “on-off” phenomenon in Parkinson’s disease  patient^.^ Recently continu- 
ous subcutaneous infusion of the dopaminergic agonist lisuride has been reported to 
control fluctuations of motor performance in clinical trials.’ In an animal model of 
Parkinson’s disease the direct infusion into the corpus striatum of dopamine has been 
reported to reduce apomorphine induced rotation in rats with unilateral substantia 
nigra lesions from 6-hydro~ydopamine.~ Initially the intraventricular application of 
dopamine was attempted in our laboratory to reverse the symptoms of bradykinesia in 
the 1-methyl-Cphenyl- 1,2,5,6 tetrahydropyridine (MPTP) model of Parkinson’s dis- 
ease in the rhesus monkey. MPTP is a byproduct of improper meperidine synthesis and 
causes a permanent parkinsonism syndrome in intravenous drug abusers.’ Subse- 
quently this compound has been used extensively in primates to effect the best animal 
model of Parkinson’s disease, both symptomatically and pathologically, developed to 
date.* However, the use of dopamine caused many undesirable behavioral side effects 
which caused us to look for a better agent. Since levodopa is relatively insoluble, we 
decided to look at other possible precursors of dopamine. For the past two years our 
laboratory has concentrated on the intraventricular administration of levodopa methyl 
ester (LDME) to reverse the symptoms of bradykinesia induced by MPTP. Addition- 
ally, we have investigated the regional advantage of the intraventricular route over 
intravenous administration. This report will detail our preliminary experience with this 
model and discuss the potential treatment advantages of intraventricular perfusion in 
the treatment of “on-off” phenomenon of Parkinson’s disease patients. 
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ACUTE INTRAVENTRICULAR INFUSION 
Ten adult rhesus monkeys were administered 1.4 mg/kg MPTP (Aldrich Chemical 
Co., Milwaukee, WI) intravenously in divided dosages which resulted in the develop- 
ment of severe bradykinesia and marked decrease of spontaneous food intake. The 
absolute amount of MPTP required to develop clinical parkinsonism showed marked 
individual variation which correlated primarily with the animal’s age with younger 
animals requiring more drug to exhibit the equivalent motor changes of the treated 
older animals. All animals required supplementary nasogastric tube feedings in the 
attempt to maintain pretreatment body weight. 
The animals subsequently underwent placement of a lateral ventricular cannula 
connected to a subgaleal Rickham reservoir or an Infusaid Model 400 pump (Infusaid 
Corp.. Norwood, MA) placed subcutaneously in the interscapular space. All surgery 
was performed using intramuscular ketamine 10 mg/kg and xylazine 2 mg/kg 
anesthesia. Postoperatively the animals received acetamenophen water for analgesia. 
The lnfusaid pump permitted the continuous perfusion of artificial cerebrospinal fluid 
between injections of intraventricular levodopa methyl ester which prevented catheter 
occlusion whereas the Rickham reservoir permitted frequent C S F  sampling following 
drug injection. Following catheter placement the animals underwent air or positive 
contrast ventriculography under intramuscular ketamine 10 mg/kg anesthesia to 
document proper catheter placement. 
Prior to LDME injection animals were videotaped for three hours to document 
spontaneous motor activity. Daily voluntary food intake by the animals was recorded. 
Following the intraventricular injection of LDME 15 mg, animals were videotaped for 
an additional three hours. Spontaneous motor activity of the animals was evaluated by 
a neurologist in a blinded manner and circling movements were measured. Changes in 
spontaneous food intake were evaluated by a review of the animal’s daily food intake 
records. 
CSF dopamine metabolite studies were performed following the evaluation of 
motor and feeding effects of intraventricular LDME. MPTP-treated rhesus monkeys 
with Rickham reservoirs connected to lateral ventricular catheters were placed in 
monkey chairs during C S F  sampling experiments. Control C S F  1 ml was obtained 
immediately preceding the intraventricular injection of LDME 15 mg. Following the 
injection hourly samples of CSF were obtained for the measurement of the dopamine 
metabolites homovanillic acid (HVA) and dihydroxyphenylacetic acid (DOPAC) and 
LDME using a HPLC system with an electrochemical detector. 
After the drug trials the animals were euthanized. The brains were immediately 
removed and placed in formalin 15%. After adequate fixation gross and microscopic 
examination were performed. 
Review of six animals videotaped before and after intraventricular LDME 
documented a 470% increase in spontaneous circling movements during the three-hour 
observation period after injection (FIGURE 1). Analysis of the animals’ movement did 
not reveal circling predominantly in one direction. Hourly measurements of move- 
ments after injection were compared to corresponding hours prior to the drug and were 
analyzed statistically using the Student’s T Test. The increase in spontaneous 
movement was statistically significant (p < 0.05). 
During the three-hour videotaped observation following intraventricular LDME 
the animals were noted to increase their spontaneous food intake greatly. Analysis of 
this behavioral change revealed a 580% increase of food intake during the day of the 
drug trial compared to the day before (FIGURE 2). The measurement of food intake of 
the day of the drug trial and the days before and after intraventricular LDME were 
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FIGURE 1. Increase of movement following 
the acute intraventricular injection of LDME 
measured as percentage of control movements 
counted in the same MFTP rhesus monkey 
immediately before drug trial (n = 6). 
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compared with the Student's T Test and the increase of spontaneous food intake was 
significant (p < 0.01). 
CSF dopamine metabolite studies have been completed thus far on two animals. A 
10-fold increase in HVA and DOPAC over baseline values after intraventricular 
LDME have been documented (FIGURE 3). Following intravenous LDME 15 mg 
minimal increases of CSF HVA and DOPAC were seen and no change of C S F  
dopamine metabolites were found following an intraventricular placebo injection of 
artificial CSF (FIGURE 4). 
DISCUSSION 
Hypotheses of the etiology of the "on-off'' phenomenon are based on the factors of 
drug absorption and transport competition causing fluctuations of levodopa plasma 
levels as well as alterations of dopamine receptor site f ~ n c t i o n . ~ " ~  Dietary intake of 
amino acids can interfere with drug absorption and transport and result in unstable 
blood levels of levodopa. Plasma levels of levodopa rise more rapidly after oral 
administration in patients on chronic compared to those patients initiating treatment. 
Lastly, some authors have proposed that leveodopa therapy results in dopamine 
receptor site hypersensitivity which would exaggerate the problems of unstable drug 
plasma levels. Measures used to treat the "on-off" phenomenon have included drug 
holidays, the administration of frequent, small dosages of levodopa, the use of 
decarboxylase inhibitors to limit peripheral metabolism, dopaminergic agonist thera- 
FIGURE 2. Spontaneous food intake measured 
by volume of the test animals on the days of the 
drug trial and the days before and after mea- 
sured in percent of food intake expected of a 
normal weight matched rhesus monkey 
(n = 6). 
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M~~~~~ 
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py, and low protein diets.’ These treatment regimens usually provide only limited 
control of the symptoms of the “on-off” phenomenon. More recently time-released 
levodopa has undergone clinical trials and has shown limited success.11*’2 The use of 
constant drug perfusion would be the obvious extention of these therapies and would 
avoid the problems associated with oral administration. 
Clinically the use of an intravenous infusion of levodopa has been reported by 
several authors.“” This approach would not be practical for chronic treatment since 
levodopa is poorly water soluble and acidic and requires large volumes of solution for 
parenteral administration. More recently a report of constant subcutaneous infusion of 
the dopaminergic agonist lisuride was published.’ For a period of 4 to 7 months three 
patients received lisuride by a portable mini-infusion pump in addition to oral levodopa 
and a decarboxylase inhibitor. Although symptomatically improved, the patients 
exhibited increased dyskinetic movements. 
In animal models of Parkinson’s disease the intraventricular and direct tissue 
infusion routes have been recently r e p ~ r t e d . ~ . ’ ~  Theoretically the intraventricular route 
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FIGURE 3. Cerebrospinal fluid dopamine metabolites HVA and DOPAC and the test drug 
LDME in ng/ml measured hourly before and after intraventricular injection of 15 mg. 
“on-off” phenomenon. This route would avoid drug absorption and transport competi- 
tion which in part result in unstable plasma drug levels. Secondly, peripheral 
metabolism would not be an issue with direct central nervous system administration. 
These two hypotheses of the “on-off” phenomenon would not be completely avoided 
using a constant subcutaneous or intravenous drug infusion. The intraventricular route 
may provide constant drug perfusion for the entire corpus striatum which would not 
occur with direct tissue infusion unless multiple catheters were utilized. However, a 
diffusion gradient from the ventricular system may become a significant issue when 
this route is used in the larger human brain resulting in differential stimulation of 
dopamine receptors. This concern will require human trials to determine if it will be 
clinically important. 
Direct intrastriatal perfusion of dopamine would require multiple catheters to 
deliver the neurotransmitter to the widespread parts of the corpus striaturn. Placement 
of these catheters would have to be precise since the tissue diffusion of dopamine was 
very limited. The necessity of multiple catheters and precise localization would result 
in  a more hazardous procedure with a higher failure rate. 








Our preliminary data suggest that the acute intraventricular administration of 
LDME transiently reverses bradykinesia in the MPTP rhesus monkey model of 
parkinsonism. An approximate 10 to 1 regional advantage was seen when comparing 
dopamine metabolites following administration of identical intraventricular or intrave- 
nous dosages. This regional advantage is particularly important since implantable 
pump systems have a limited capacity and the risk of infection occurs with every pump 
refill. Importantly, LDME is freely water soluble and could be infused in small, 
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FIGURE 4. Cerebrospinal fluid analysis of (A) HVA and (B) DOPAC in ng/ml measured 
hourly following intraventricular ( I )  LDME 15 mg, intravenous (IV) LDME 15 mg and the 
intraventricular injection of a placebo, Elliott's B solution. 
concentrated volumes which is not possible with levodopa. More clinical experience 
will be necessary to determine if LDME like levodopa is generally better tolerated than 
many of the dopaminergic agonists. 
Additional research is necessary to determine if this therapeutic approach will be 
practical for patients. The issue of drug stability in solution for periods of three to four 
weeks will have to be resolved. Additionally chronic efficacy and toxicity will have to 
be determined before widespread clinical use will be approved. Our positive experience 
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with the intraventricular administration of LDME warrants its further investigation in 
the attempt to find a therapy for the  problem of “on-off” phenomenon. 
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